August 10, 2021

POINT Biopharma Announces Early Completion of Enrollment and Initial Dosing in the Lead-In of its Phase 3 SPLASH study of PNT2002 for mCRPC

Announcing the completion of enrollment and initial dosing of the 25-patient safety and dosimetry lead-in of the Company’s Phase 3 SPLASH study evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer

July 21, 2021

POINT Biopharma and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Isotopia to supply POINT with no-carrier-added Lu-177 for use in POINT’s Indianapolis, IN radioligand production facility

June 30, 2021

POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company

Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”. Gross proceeds from the transaction totaled approximately $286.7 million.

June 28, 2021

POINT Biopharma Strengthens Senior Management Team with Appointment of Dr. Myra Rosario Herrle as EVP, Regulatory Affairs

POINT announced today the appointment of Myra Herrle, Ph.D., R.Ph., RAC as Executive Vice President of Regulatory Affairs. Dr. Herrle brings over 27 years of experience in the pharmaceutical industry in areas such as regulatory affairs ...

June 4, 2021

POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC

POINT today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company’s investigational 177Lu-PSMA targeted radioligand therapy.